| Autor: |
Chen T; New York University, New York, NY., Levitt J, Geller L |
| Jazyk: |
angličtina |
| Zdroj: |
Dermatology online journal [Dermatol Online J] 2017 Jan 15; Vol. 23 (1). Date of Electronic Publication: 2017 Jan 15. |
| Abstrakt: |
Recurrent erythema multiforme with oralinvolvement is therapeutically challenging.Apremilast has been used with success in resolvingthe oral aphthae of Behçet disease, prompting theuse of the drug in patients with oral erosions fromerythema multiforme. Three patients with oralerythema multiforme were given apremilast at dosesof 30-60mg daily. Complete clearance of the lesionswere observed in all three patients, including thoserefractory to other standard therapies. Apremilast maypresent an effective option for recurrent erythemamultiforme for patients who have failed trials antiviraland immunosuppressive therapies. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
